4 Merger and Acquisitions Stock Stories For Tuesday Appraisal

Anheuser-Busch InBev (NYSE: BUD): Current price $92.29

Anheuser-Busch and Grupo Modelo, S.A.B. de C.V announced Tuesday that the former has successfully finalized its merger with Grupo Modelo in a transaction valued at $20.1 billion, or $9.15 per share.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

BUD

Office Depot (NYSE:ODP): Current price $4.31

On Tuesday, the worldwide supplier of office supplies and services, said that it will sell its 50-percent interest in the Latin American Joint Venture Office Depot de Mexico S.A. de C.V. to Grupo Gigante, S.A.B. de C.V. for the 8,777.36 million pesos in cash. The agreement is contingent upon on receiving approvals from Mexican regulatory officials and Grupo Gigante S.A.B. de C.V. shareholders, which Office Depot expects will be secured within 30 days. After the transaction closes, Grupo Gigante, S.A.B. de C.V. and its affiliates will hold a 100-percent ownership of Office Depot de Mexico.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

ODP

Smithfield Foods (NYSE:SFD): Current price $32.92

Smithfield’s biggest shareholder, Continental Grain Co, reported Monday that it would divest its interest in the pork producer, thus averting an impending proxy fight following Shuanghui International Holdings moving in to acquire Smithfield in a multi-billion dollar deal. Continental was first formed in 1813 as a grain-trading company in Arlon, Belgium. Reuters data indicates that it held a 5.84 percent stake in Smithfield as of April 25.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

SFD

Zimmer Holdings (NYSE:ZMH): Current price $77.32

Zimmer announced Tuesday that it has bought NORMED Medizin-Technik GmbH, which provides innovative technologies for the foot and ankle, hand and wrist reconstruction and trauma markets. The German firm develops a wide array of specialized plates, screws and instruments, among which include systems for bone reconstruction and fracture repair, fusion procedures and external fixation.  The purchase of NORMED will reinforce Zimmer’s Extremities and Trauma product portfolios and new product development capabilities in the quickly-growing foot and ankle and hand and wrist segments.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

ZMH

Don’t Miss: Can Bank of America’s Bid to End Crisis-Era Litigation Live?

More from The Cheat Sheet